WLY
Fiscal year ends April Quarters are offset from the calendar — Q1 is May–Jul

John Wiley & Sons, Inc. is a publishing and research intelligence company founded in 1807. The company operates through two primary segments: Research and Learning. The Research segment publishes over 1,900 scientific, technical, medical, and scholarly journals, providing content and services in physical sciences, engineering, health sciences, social sciences, and life sciences. It serves academic, corporate, and government institutions, researchers, and professional societies globally, with significant operations in the United States and the United Kingdom. Key offerings include journal subscriptions, transformational agreements, open access publishing, and the Wiley Online Library platform. The Learning segment provides academic and professional publishing, courseware, and assessments for students, educators, and professionals. The company also offers research intelligence solutions for corporate R&D teams, including clinical outcome assessments and AI-driven data analytics. Wiley partners with numerous professional societies, including the American Cancer Society, the American Heart Association, and the American Geophysical Union, to publish their journals. The company utilizes the Atypon Experience Platform for publishing workflows and offers adaptive digital courseware and interactive textbooks.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Publishing Homepage wiley.com
Sector Communication Services IR page investors.wiley.com/overview/default.aspx
Tags
academic publishing, scientific journals, research intelligence, open access, digital courseware, professional education, clinical outcome assessments, ai data analytics, society publishing, peer review, Wiley Online Library, Atypon Experience Platform, Wiley Applied Research Intelligence, ARI Professional Services, Advanced Medicine, Advanced Healthy Aging
Press page —

Metrics

Valuation  
Market cap $ 2.582B
Market cap (USD) $ 2.582B
P/E 12.87
PEG 0.10
P/BV 3.24
P/S 1.55
P/OCF 8.89
P/FCF 10.76
Dividend yield —
Turnover / mcap —
Returns  
ROE 27.7%
ROI 14.5%
ROIC 18.1%
Profit margin 13.2%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 134.3%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 162.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 68
Quality score 27.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.677B 1.678B 1.873B 2.02B 2.083B 1.942B 1.831B 1.8B 1.796B 1.719B 1.727B 1.822B 1.775B 1.761B 1.783B 1.743B 1.699B 1.611B 1.674B 1.235B 1.044B 974.048M 922.962M 853.971M — 613.79M 594.815M
Net profit 221.617M 84.161M -200.319M 17.233M 148.309M 148.256M -74.287M 168.263M 192.186M 113.643M 145.782M 176.868M 160.51M 144.225M 212.746M 171.889M 143.543M 128.258M 147.536M 99.619M 110.328M 83.841M 88.84M 87.275M 57.316M 58.918M 52.388M
Free cash flow 209.353M 141.118M 131.558M 195.916M 250.257M 282.516M 199.842M 173.664M 267.613M 203.801M 256.252M 286.001M 290.66M 278.333M 312.271M 321.226M 266.896M 295.246M 229.82M 189.149M 221.287M 216.66M 182.99M 105.907M 106.723M 102.358M 116.035M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 38.1 44.56 38.71 38.77 53.73 54.2 37.49 46.96 63.7 53.8 48.89 61.14 57.64 38.95 47.61 50.86 — — — — — — — — — — —
Price performance 12m -0.14 0.15 -0 -0.28 -0.01 0.45 -0.2 -0.26 0.18 0.1 -0.2 0.06 0.48 -0.18 -0.06 — — — — — — — — — — — —

Filed figures

Figure Apr 2017 Apr 2018 Apr 2019 Apr 2020 Apr 2021 Apr 2022 Apr 2023 Apr 2024 Apr 2025 Apr 2026
Balance sheet detail
Trade receivables (USD) 189M 212M 295M 309M 312M 332M 310M 224M 228M 244M
↳ YoY growth +12.6% +12.6% +38.8% +4.9% +0.7% +6.5% -6.6% -27.7% +1.9% +6.9%
↳ 5y CAGR +1.9% +5.6% +14.5% +16.0% +13.2% +12.0% +7.9% -5.3% -5.9% -4.8%
Borrowings, current (USD) — — 0.00 9.38M 12.5M 18.8M 5M 7.5M 10M 12.5M
Borrowings, non-current (USD) 365M 360M 479M 766M 809M 768M 743M 767M 789M 671M
Lease liabilities (USD) — — 0.00 182M 168M 153M 135M 113M 99.8M 85.5M
Cash and deposits (USD) 58.5M 170M 92.9M 202M 93.8M 100M 107M 83.2M 85.9M 75.6M
Intangible assets (USD) 828M 848M 866M 807M 1.02B 931M 855M 616M 595M 579M
Right-of-use assets (USD) — — 0.00 143M 121M 112M 91.2M 69.1M 66.1M 57.1M
Net debt (borrowings + leases - cash) (USD) 306M 190M 386M 754M 896M 840M 777M 804M 813M 693M
Cash flow detail
Operating cash flow (USD) 315M 382M 251M 288M 360M 339M 277M 208M 203M 261M
Purchases of property, plant and equipment (USD) -111M -114M -77.2M -88.6M -77.4M -88.8M -81.2M -76.1M -61.5M -51.2M
Purchases of intangible assets (USD) -28.8M -26.7M -9.49M -1.84M -29.9M -5.84M -2.58M -8.41M — —
Change in receivables (cash effect) (USD) — — — 2.75M 2.19M 20.4M -21.8M 85.9M -4.21M -15.8M
Change in inventories (cash effect) (USD) 8M 13.5M 3.82M -2.71M 7.84M 2.31M -522,000 5.44M -1.42M 6.72M
Dividends paid (cash effect) (USD) -71.5M -73.5M -75.8M -76.7M -76.9M -77.2M -77.3M -77M -76.1M -74.4M
Share buybacks (cash effect) (USD) -50.3M -39.7M -60M -46.6M -15.8M -30M -35M -45.1M -60.4M -100M
Interest paid (cash effect) (USD) -15.7M -12.2M -14.9M -23.6M -17.2M -17.8M -36.1M -47.1M -51.3M -43.1M
Income taxes paid (cash effect) (USD) -33.7M -48.7M -48.3M -41.5M -41.1M -48.9M -50.9M -50.8M -53.9M -58.4M
Share-based compensation (USD) 17.6M 11.2M 18.3M 20M 22M 25.7M 26.5M 25M 22.2M 20.6M
Operating cash flow before change in receivables (USD) — — — 286M 358M 319M 299M 122M 207M 276M
Free cash flow (OCF - PPE - intangibles) (USD) 204M 241M 164M 198M 253M 244M 193M 123M 141M 209M
Income detail
Total comprehensive income (USD) 54M 260M 99.1M -141M 233M 131M -3.52M -200M 134M 258M
Comprehensive income to owners (USD) 54M 260M 99.1M -141M 233M 131M -3.52M -200M 134M 258M
Provision for credit losses (USD) — — — — — 4.03M 347,000 — — —
Credit cost ratio (credit losses / average receivables) (%) — — — — — 1.3% 0.1% — — —
Reported Jun 29, 2018 Jun 29, 2018 Sep 6, 2019 Jun 26, 2020 Jul 6, 2021 Jun 24, 2022 Jun 26, 2023 Jun 26, 2024 Jun 25, 2025 Jun 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

11/03/2026

Download this Press Release PDF Format (opens in new window)

Award showcases early-career researchers for their outstanding and innovative interdisciplinary work and exceptional promise as research leaders.

HOBOKEN, NJ—Wiley has named 12 early-career researchers in seven different countries as winners of the 2026 Advanced Science Young Innovator Award, one of the most competitive honors for young scientists in interdisciplinary science.

The winners—announced yesterday at Wiley’s Advanced Summit in London—were selected from a highly competitive pool of 382 applicants across 52 countries. They represent the highest caliber of emerging scientists who are translating discoveries into real-world impact.

Advanced Science is a prestigious, open access, interdisciplinary journal publishing best-in-class fundamental and applied research in materials science, physics, chemistry, engineering, and medical and life sciences. It is part of the Advanced Portfolio, Wiley’s premier collection of impactful, multidisciplinary journals—one of the world’s top-tier research journal series—that disseminate the best science from well-established and emerging researchers.

The Young Innovator Award, now in its third year, is a coveted recognition among early-career researchers globally. It identifies scientists whose interdisciplinary approaches are bridging fields and accelerating the path from laboratory breakthrough to practical application in materials science and chemistry, physics and engineering, life and health sciences, earth and environmental sciences, and social sciences.

"These researchers show what the next generation of scientific leadership looks like: rigorous, ambitious, and focused on impact," said Kirsten Severing, editor-in-chief of Advanced Science. "The strength and international breadth of this year's applications made for an exceptionally competitive selection, making these winners reflective of the future of scientific leadership."

The winners were selected based on the originality of their research, demonstrated impact potential, and ability to work across traditional scientific boundaries. The rigorous selection process evaluated both the quality of their published work and the trajectory of their contributions to solving critical challenges in the selected disciplines.

The following individuals are this year’s winners:

  • Jie-Jie Chen, Earth & Environmental Sciences, University of Science and Technology of China, China
  • Bowen Li, Health Sciences, University of Toronto, Canada
  • Wu Li, Chemistry, Wuhan University, China
  • Lu Lu**,** Computer Science, Yale University, USA
  • Wei Lv, Materials, Tsinghua Shenzhen International Graduate School, China
  • Phillip Milner**,** Chemistry, Cornell University, USA
  • Zachariah Allen Page, Materials, The University of Texas at Austin, USA
  • Stanisa Raspopovic, Engineering, Medical University Vienna, Austria
  • Francesca Santoro, Engineering, Forschungszentrum Jülich and RWTH Aachen, Germany
  • Daisy Radha Singla, Health Sciences, University of Toronto, Canada
  • Roser Vento-Tormo, Life Sciences, Wellcome Sanger Institute, United Kingdom
  • Xiaoyu (Rayne) Zheng, Engineering, UC Berkeley, USA

Each winner receives a $1,000 research prize and amplification through Advanced Science's global platform—recognition that accelerates collaboration opportunities, funding, and real-world application of their work.

Learn more about the winners and their research at: Advanced Science Young Innovator Award

About Wiley

Wiley (NYSE: WLY) is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com . Follow us on Facebook , X , LinkedIn and Instagram .

10/29/2026

Download this Press Release PDF Format (opens in new window)

New browser-based platform helps researchers search millions of trusted reference spectra, identify unknown compounds, and manage, validate, publish, and share analytical datasets

HOBOKEN, N.J. — Wiley (NYSE: WLY), a global leader in authoritative content and research intelligence, today launched Wiley Analytical Lab, a new software-as-a-service (SaaS) platform that gives researchers access to its trusted spectral data, compound identification tools, and analytical data management capabilities through one modern online environment. 

Scientific research increasingly depends on both trusted reference data and the ability to manage and share the data generated in the lab. Yet these activities often take place across separate systems, locally installed software, and disconnected repositories. Wiley Analytical Lab addresses that problem by making critical analytical capabilities easier to access across institutions and research teams, while supporting the path from spectral search and identification through data management and publication. 

Wiley Analytical Lab gives researchers a one-stop shop where they can easily access the following trusted Wiley tools to perform multiple tasks: 

  • SpectraBase — Search millions of trusted reference spectra 

  • KnowItAll AnyWare — Upload experimental spectra and identify unknown compounds 

  • Wiley Data Hub — Manage, validate, publish, and share analytical datasets 

The platform is built on Wiley’s expertise in spectral data and scientific publishing, helping researchers work more efficiently and with greater confidence. 

The launch advances Wiley’s strategy to transform authoritative scientific knowledge and data into scalable, workflow-relevant digital solutions. By delivering these capabilities through a SaaS platform, Wiley can broaden access today while creating a foundation for continued product expansion and future innovation across the research workflow. 

“Wiley Analytical Lab represents an important step in how we turn trusted scientific data into intelligence researchers can use directly in their work,” said Armughan Rafat, Wiley senior vice president and chief AI and data analytics officer. “Researchers need more than just access to information; they need modern, connected tools that help them move from an unknown sample to a confident answer and from experimental data to published, reusable science. By combining Wiley’s trusted spectral content, analytical capabilities, and publishing expertise in a scalable SaaS environment, we are helping researchers work faster while strengthening the foundation for future data- and AI-driven innovation.” 

Unlike fragmented or instrument-specific solutions, Wiley Analytical Lab provides a vendor-neutral online environment that supports researchers working across instruments, formats, locations, and teams. The browser-based SaaS platform complements Wiley’s recently launched spectroscopy API portfolio and builds on capabilities available in its expert desktop KnowItAll software. 

Wiley Analytical Lab will initially be available through KnowItAll Campus-Wide Solutions for universities and KnowItAll Complete Multi-User Licensing for corporate and government organizations.  

10/29/2026

Download this Press Release PDF Format (opens in new window)

UT MD Anderson symposium will convene more than 1,500 leading scientists, clinicians, researchers, and innovators to share discoveries, foster collaboration and advance the frontiers of science.

Hoboken, NJ — Wiley's Advanced Portfolio will support scientific exchange and amplify breakthrough research from leading scientists and clinicians in immunology, cancer biology and human health at the 2026 James P. Allison Institute scientific symposium at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Following the theme “Immune Set Points: Stress, Wellness, and System Control,” the symposium—taking place on October 30, 2026 at the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park—will convene more than 1,500 leading scientists, clinicians, journal editors, research trainees and innovators at the forefront of cancer immunology and immunotherapy research. Their purpose is to share groundbreaking discoveries, foster collaboration, and advance the frontiers of science.

"The Allison Institute scientific symposium represents the kind of interdisciplinary scientific exchange that is essential to advancing our understanding of cancer and human health,” said Allyn Molina, group vice president of publishing development at Wiley. “This symposium offers an amazing opportunity to connect research communities and drive forward ideas that can shape the future of health and medicine. Wiley is proud to support this community and the next generation of discoveries."

The Allison Institute was established at UT MD Anderson to advance exceptional discovery, translational and clinical research that integrates immunobiology across disciplines. The institute builds on the legacy of its namesake, James P. Allison, Ph.D. who was awarded the 2018 Nobel Prize in Physiology or Medicine for fundamental discoveries in T cell biology that led to the invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer. These discoveries helped to launch the field of cancer immunotherapy.

The 2026 program features a plenary keynote from Nobel laureate William G. Kaelin Jr., M.D., scientific sessions across three tracks, a trainee poster session, and a panel featuring six Nobel laureates moderated by TIME Senior Health Correspondent Alice Park.

This symposium coincides with the continuing expansion of Wiley’s Advanced Portfolio into life and health sciences, including the recent launches of new journals Advanced Oncology, Advanced Immunology, and Advanced Healthy Aging, disciplines which are central to the symposium's scientific focus.

At the symposium, the Advanced Portfolio will bring its commitment to publishing top-tier science into the room, including:

  • Supporting a dedicated dinner with a guest speaker, bringing the community together for deeper discussion;
  • Fostering awards to recognize emerging scientific talent and honor the rigorous, high-impact research the Advanced journals exist to publish;
  • Supporting an on-site podcast series to carry that same standard into conversation, with leading researchers exploring key themes from the presentations, emerging trends in oncology, immunology and human health, and the scientific questions shaping the next generation of discovery.

Prompts

John Wiley & Sons, Inc. (ticker WLY), listed in United States.

Company History

Date Change Detail
Aug 15, 2019 Renamed WILEY JOHN & SONS, INC. → JOHN WILEY & SONS, INC.

ETFs Holding John Wiley & Sons, Inc.

ETF Weight in ETF Shares Market value As of
NBSM 1.51% 33,153 $ 1.737M Aug 31, 2026
CGV 1.41% 34,864 $ 1.82M Jul 31, 2026
JSML 1.04% 72,115 $ 3.764M Jul 31, 2026
CVAR 0.87% 7,174 $ 374.483K Jul 31, 2026
JPSV 0.52% 2,929 $ 146.948K Nov 17, 2026
SCDS 0.49% 886 $ 44.451K Nov 17, 2026
SIXL 0.41% 17,403 $ 860.404K Nov 12, 2026
FESM 0.34% 403,150 $ 19.557M Jun 30, 2026
RUSC 0.20% 3,324 $ 161.247K Jun 30, 2026
IVSS 0.20% 1,082 $ 52.488K Jun 30, 2026
VFQY 0.15% 14,891 $ 780.139K Aug 31, 2026
VFMF 0.15% 27,625 $ 1.447M Aug 31, 2026
FSEG 0.14% 164 $ 7,955.64 Jun 30, 2026
AVSC 0.13% 81,927 $ 4.127M Nov 16, 2026
FSEV 0.12% 170 $ 8,246.70 Jun 30, 2026
AFSM 0.11% 3,285 $ 165.498K Nov 16, 2026
VFMO 0.09% 34,300 $ 1.797M Aug 31, 2026
VFVA 0.09% 16,785 $ 879.366K Aug 31, 2026
DFAT 0.08% 523,995 $ 25.906M Nov 12, 2026
JMEE 0.08% 47,015 $ 2.359M Nov 17, 2026
RESM 0.08% 60 $ 2,910.60 Jun 30, 2026
EBI 0.07% 9,615 $ 503.73K Aug 31, 2026
SMDX 0.07% 1,791 $ 90.231K Nov 17, 2026
DFAS 0.05% 335,612 $ 16.593M Nov 12, 2026
DFSV 0.04% 205,664 $ 10.168M Nov 12, 2026
DXUV 0.02% 31,085 $ 1.537M Nov 12, 2026
DFSU 0.01% 5,829 $ 288.186K Nov 12, 2026
DFUV 0.01% 35,850 $ 1.772M Nov 12, 2026
MSSM 0.01% 1,527 $ 80K Aug 31, 2026
DFAC 0.01% 176,045 $ 8.704M Nov 12, 2026
DCOR 0.01% 63,679 $ 3.148M Nov 12, 2026
DFAU 0.01% 15,071 $ 745.11K Nov 12, 2026
DFUS 0.00% 11,709 $ 578.893K Nov 12, 2026
AVSU 0.00% 196 $ 9,874.48 Nov 16, 2026
NTRL 0.00% 3,172 $ 0.00 Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
WLY canonical Common share — US nyse 47.76 USD 2026-09-30
WLYB Common share — US nyse 48.93 USD 2026-09-30